|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
antineoplastic agent
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EB04
|
|
gptkbp:bioavailability
|
unknown
|
|
gptkbp:brand
|
gptkb:Tagrisso
|
|
gptkbp:CASNumber
|
1421373-65-0
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:discoveredBy
|
gptkb:AstraZeneca
|
|
gptkbp:eliminationHalfLife
|
48 hours
|
|
gptkbp:hasMolecularFormula
|
C28H33N7O2
|
|
gptkbp:hasSMILES
|
COC1=CC2=C(C=C1)N=C(N2)NCC3=CC=C(C=C3)C4=NC5=C(C=CC(=C5N4)OC)CNC6=CC=CC=C6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
osimertinib
|
|
gptkbp:indication
|
EGFR T790M mutation-positive NSCLC
|
|
gptkbp:KEGGID
|
D10568
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
irreversible EGFR inhibitor
|
|
gptkbp:metabolism
|
liver (CYP3A4/5)
|
|
gptkbp:molecularWeight
|
499.6 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB09330
CHEMBL3185146
58129638
71512363
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
rash
QT prolongation
interstitial lung disease
dry skin
nail toxicity
|
|
gptkbp:synonym
|
gptkb:Tagrisso
gptkb:AZD9291
|
|
gptkbp:target
|
gptkb:EGFR
|
|
gptkbp:UNII
|
7A5O4W8G6D
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
|
|
gptkbp:bfsParent
|
gptkb:EGFR
gptkb:EGFR_gene
gptkb:P15056
gptkb:P42338
gptkb:T790M
gptkb:EGFR_signaling_pathway
gptkb:Tagrisso
|
|
gptkbp:bfsLayer
|
6
|